The trial between Elon Musk and OpenAI concluded with lawyers making closing arguments focused on whether OpenAI CEO Sam Altman was truthful, especially regarding his congressional testimony about equity stakes. The case highlights broader concerns about trust in AI companies, which remain largely private and opaque. Both Altman and Musk faced scrutiny over honesty, but their differing approaches to truthfulness were noted. The jury's decision will determine if OpenAI acted improperly as it shifted toward a more profit-driven model.
Design Therapeutics, a clinical-stage biotech company, will announce data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2, a treatment for Friedreich’s ataxia, on May 18, 2026. The company will host a live webcast and conference call to discu...
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
The iShares 20+ Year Treasury Bond ETF (TLT) saw $122 million in outflows last week amid rising US bond yields driven by higher inflation and hawkish Federal Reserve signals. April's inflation data showed consumer prices jumping to 3.8% and producer ...
A Colorado bankruptcy judge temporarily closed then agreed to reopen what could be the largest Chapter 11 case in state history involving 440,040 veterans from the Camp Lejeune Justice Act (CLJA) Settlement Club. The case concerns a $44.4 billion set...
Dianthus Therapeutics' Chief Financial Officer sold 8,224 shares of the company, generating approximately $739,000 from the transaction. This insider sale could indicate the CFO's personal financial decision or a strategic move, but it may raise ques...
